Global Helicobacter Pylori Diagnostics Industry

Global Helicobacter Pylori Diagnostics Industry

  • April 2021 •
  • 278 pages •
  • Report ID: 5956933 •
  • Format: PDF
Abstract:
- Global Helicobacter Pylori Diagnostics Market to Reach $729.2 Million by 2027
- Amid the COVID-19 crisis, the global market for Helicobacter Pylori Diagnostics estimated at US$489.2 Million in the year 2020, is projected to reach a revised size of US$729.2 Million by 2027, growing at aCAGR of 5.9% over the period 2020-2027. Invasive, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$341.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Invasive segment is readjusted to a revised 6.3% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $132.5 Million, While China is Forecast to Grow at 8.9% CAGR
- The Helicobacter Pylori Diagnostics market in the U.S. is estimated at US$132.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$153.3 Million by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

- Select Competitors (Total 44 Featured) -
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • DiaSorin SpA
  • Exalenz Bioscience Ltd.
  • F. Hoffmann-La Roche AG
  • Halyard Health, Inc.
  • Meridian Bioscience, Inc.
  • Quidel Corporation
  • Thermo Fisher Scientific, Inc.